Decreased high-density lipoprotein cholesterol levels in polyarticular juvenile idiopathic arthritis. 2011

Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Brazil.

OBJECTIVE To investigate the prevalence of dyslipoproteinemia in a homogeneous cohort of polyarticular juvenile idiopathic arthritis patients. METHODS Based on the National Cholesterol Education Program, fasting lipoprotein levels and risk levels for coronary artery disease were determined in 28 patients with polyarticular juvenile idiopathic arthritis. The exclusion criteria included diabetes, thyroid dysfunction, smoking, proteinuria, lipid-lowering drugs, and hormone/diuretic therapy. Disease activity, disease duration, and therapy with corticosteroids and/or chloroquine were defined at the time of lipid measurements. RESULTS Dyslipoproteinemia was identified in 20 of the 28 (71%) patients with polyarticular juvenile idiopathic arthritis. The primary lipoprotein risk factor was decreased high-density lipoprotein cholesterol (57%), followed by elevated levels of low-density lipoprotein cholesterol (18%), triglycerides (14%), and total cholesterol (7%). The male patients had decreased high-density lipoprotein cholesterol levels than the female patients (p<0.05). The incidence of decreased high-density lipoprotein cholesterol levels did not seem to be affected by disease activity or therapy because the incidence was similar in patients with active or inactive disease, with or without corticosteroid use and with or without chloroquine use. In addition, the frequency of decreased high-density lipoprotein cholesterol levels was similar in patients with short (≤5 years) vs. long (>5 years) disease duration. CONCLUSIONS Dyslipoproteinemia is highly prevalent in patients with polyarticular juvenile idiopathic arthritis and is primarily related to decreased high-density lipoprotein cholesterol levels; therefore, early intervention is essential.

UI MeSH Term Description Entries
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D004812 Epidemiologic Methods Research techniques that focus on study designs and data gathering methods in human and animal populations. Epidemiologic Method,Epidemiological Methods,Methods, Epidemiologic,Epidemiological Method,Method, Epidemiologic,Method, Epidemiological,Methods, Epidemiological
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001171 Arthritis, Juvenile Arthritis in children, with onset before 16 years of age. The terms juvenile rheumatoid arthritis (JRA) and juvenile idiopathic arthritis (JIA) refer to classification systems for chronic arthritis in children. Only one subtype of juvenile arthritis (polyarticular-onset, rheumatoid factor-positive) clinically resembles adult rheumatoid arthritis and is considered its childhood equivalent. Arthritis, Juvenile Chronic,Arthritis, Juvenile Idiopathic,Arthritis, Juvenile Rheumatoid,Childhood Arthritis,PCJIA,PJIA Polyarticular Juvenile Idiopathic Arthritis,Polyarticular Juvenile Idiopathic Arthritis,Polyarticular-Course Juvenile Idiopathic Arthritis,Still's Disease, Juvenile-Onset,Enthesitis-Related Arthritis, Juvenile,Juvenile Chronic Arthritis,Juvenile Idiopathic Arthritis,Juvenile Rheumatoid Arthritis,Juvenile-Onset Still Disease,Juvenile-Onset Stills Disease,Oligoarthritis, Juvenile,Polyarthritis, Juvenile, Rheumatoid Factor Negative,Polyarthritis, Juvenile, Rheumatoid Factor Positive,Psoriatic Arthritis, Juvenile,Still Disease, Juvenile-Onset,Systemic Arthritis, Juvenile,Arthritides, Childhood,Arthritis, Childhood,Arthritis, Juvenile Enthesitis-Related,Arthritis, Juvenile Psoriatic,Arthritis, Juvenile Systemic,Childhood Arthritides,Chronic Arthritis, Juvenile,Enthesitis Related Arthritis, Juvenile,Idiopathic Arthritis, Juvenile,Juvenile Arthritis,Juvenile Enthesitis-Related Arthritis,Juvenile Oligoarthritis,Juvenile Onset Still Disease,Juvenile Onset Stills Disease,Juvenile Psoriatic Arthritis,Juvenile Systemic Arthritis,Juvenile-Onset Still's Disease,Rheumatoid Arthritis, Juvenile,Still Disease, Juvenile Onset,Still's Disease, Juvenile Onset,Stills Disease, Juvenile-Onset
D012737 Sex Factors Maleness or femaleness as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or effect of a circumstance. It is used with human or animal concepts but should be differentiated from SEX CHARACTERISTICS, anatomical or physiological manifestations of sex, and from SEX DISTRIBUTION, the number of males and females in given circumstances. Factor, Sex,Factors, Sex,Sex Factor
D050171 Dyslipidemias Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL. Dyslipoproteinemias,Dyslipidemia,Dyslipoproteinemia

Related Publications

Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
December 2009, The Journal of pediatrics,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
November 1979, The Journal of clinical endocrinology and metabolism,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
January 2010, Clinical and experimental rheumatology,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
April 1984, Presse medicale (Paris, France : 1983),
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
May 1989, Southern medical journal,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
April 1993, Annals of internal medicine,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
February 2022, Journal of clinical medicine,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
June 2012, Rheumatology international,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
February 1979, Atherosclerosis,
Roberta Gonçalves Marangoni, and Andre L Hayata, and Eduardo F Borba, and Pedro M Azevedo, and Eloisa Bonfá, and Claudia Goldenstein Schainberg
January 2014, Clinical epidemiology,
Copied contents to your clipboard!